ES2105333T3 - Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma. - Google Patents

Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.

Info

Publication number
ES2105333T3
ES2105333T3 ES93923372T ES93923372T ES2105333T3 ES 2105333 T3 ES2105333 T3 ES 2105333T3 ES 93923372 T ES93923372 T ES 93923372T ES 93923372 T ES93923372 T ES 93923372T ES 2105333 T3 ES2105333 T3 ES 2105333T3
Authority
ES
Spain
Prior art keywords
prostaglandins
combinations
glaucoma
treatment
clonidine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923372T
Other languages
English (en)
Inventor
Louis Desantis Jr
Verney L Sallee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of ES2105333T3 publication Critical patent/ES2105333T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LAS COMBINACIONES DE AL MENOS UN DERIVADO DE LA CLONIDINA Y DE AL MENOS UNA PROSTAGLANDINA SE UTILIZAR PARA TRATAR EL GLAUCOMA Y LA HIPERTENSION OCULAR SIN QUE APAREZCAN LOS EFECTOS SECUNDARIOS NORMALMENTE ASOCIADOS A LA ADMINISTRACION TOPICA DE PROSTAGLANDINAS.
ES93923372T 1992-10-13 1993-10-12 Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma. Expired - Lifetime ES2105333T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96006592A 1992-10-13 1992-10-13

Publications (1)

Publication Number Publication Date
ES2105333T3 true ES2105333T3 (es) 1997-10-16

Family

ID=25502747

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923372T Expired - Lifetime ES2105333T3 (es) 1992-10-13 1993-10-12 Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.

Country Status (9)

Country Link
US (3) US5480900A (es)
EP (1) EP0664707B1 (es)
JP (1) JP3002258B2 (es)
AT (1) ATE153855T1 (es)
AU (1) AU674038B2 (es)
CA (1) CA2146127C (es)
DE (1) DE69311361T2 (es)
ES (1) ES2105333T3 (es)
WO (1) WO1994008585A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
DE4330177A1 (de) * 1993-08-31 1995-03-02 Schering Ag Neue 9-Chlor-prostaglandin-derivate
WO1996013267A2 (en) * 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU5258698A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
US6172109B1 (en) 1997-03-07 2001-01-09 Alcon Laboratories, Inc. 13-Thia prostaglandins for use in glaucoma therapy
SE9702706D0 (sv) * 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
AU5114499A (en) * 1998-07-21 2000-02-14 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6417228B1 (en) 1998-11-02 2002-07-09 Alcon Manufacturing, Ltd.. 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
US6211226B1 (en) 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
US6160013A (en) * 1998-12-17 2000-12-12 Alcon Laboratories, Inc. 14-aza prostaglandins for the treatment of glaucoma and ocular hypertension
WO2000038667A2 (en) * 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
AU763715B2 (en) * 1999-03-05 2003-07-31 Duke University C16 unsaturated fp-selective prostaglandins analogs
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020198210A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
WO2002089853A2 (en) * 2001-05-03 2002-11-14 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
ES2431640T3 (es) * 2003-08-21 2013-11-27 Sucampo Ag Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad
BRPI0418245B8 (pt) 2004-01-05 2021-05-25 Nicox Sa composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
EP1899295A2 (en) * 2005-06-29 2008-03-19 Pfizer, Inc. Prostaglandin derivatives
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
WO2013003729A1 (en) * 2011-06-29 2013-01-03 The Penn State Research Foundation Compositions, methods and kits for treating leukemia
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
HK1222810A1 (zh) 2012-05-03 2017-07-14 麦提疗法有限公司 治疗开角型青光眼和高眼压症的药物递送系统和方法
CN113230021A (zh) 2015-01-12 2021-08-10 科达莱昂治疗公司 微滴递送设备和方法
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US11058691B2 (en) 2016-11-08 2021-07-13 Nicox S.A. Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma
CN109906120A (zh) 2017-01-20 2019-06-18 科达莱昂治疗公司 压电流体分配器
WO2019113483A1 (en) 2017-12-08 2019-06-13 Kedalion Therapeutics, Inc. Fluid delivery alignment system
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
US20190314197A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
WO2020010116A1 (en) 2018-07-03 2020-01-09 Kedalion Therapeutics, Inc. Topical ocular delivery devices and methods for using the same
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
EP4120973A4 (en) 2020-04-17 2024-04-17 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
CN115768384A (zh) 2020-04-17 2023-03-07 科达隆治疗公司 流体动力致动的不含防腐剂分配系统

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202660A (en) * 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
DE1670274A1 (de) * 1966-10-31 1970-07-16 Boehringer Sohn Ingelheim Neues Verfahren zur Herstellung von 2-Arylamino-1,3-diazacycloalkenen-(2)
US3755426A (en) * 1971-07-02 1973-08-28 American Home Prod 10-haloprostaglandin-a derivatives
CA1045131A (en) * 1972-07-24 1978-12-26 Middleton B. Floyd (Jr.) Derivatives of 9-hydroxy-13-trans-prostenoic acid
US3873607A (en) * 1972-07-24 1975-03-25 American Cyanamid Co 3-Oxa(and thia) 11-deoxy PGE
US4110368A (en) * 1972-07-24 1978-08-29 American Cyanamid Company Hydro substituted prostanoic acids and esters
US3884969A (en) * 1973-04-20 1975-05-20 American Cyanamid Co Novel prostaglandins
US4029681A (en) * 1976-02-13 1977-06-14 The Upjohn Company 13,14-Didehydro-PG analogs
US4321405A (en) * 1976-03-03 1982-03-23 American Cyanamid Company 15,16-Dioxy prostenoic acids and esters
US4097489A (en) * 1977-06-17 1978-06-27 The Upjohn Company 9-Deoxy-9α,6-nitrilo or 6,9α-imino-PGF compounds
US4343949A (en) * 1977-09-22 1982-08-10 American Cyanamid Company Novel 2-substituted-3,4-epoxycyclopentan-1-ones, 2-substituted-3,4-epoxycyclopentan-1-ols, and various 2-substituted-cyclopentenones
US4288616A (en) * 1979-04-02 1981-09-08 The Upjohn Company 13,14-Didehydro-11-deoxy-11-hydroxymethyl-19-oxo-PGF2 compounds
US4291175A (en) * 1980-04-03 1981-09-22 American Cyanamid Company 1-Hydroxymethyl-11-deoxy-15-hydroxy-prosten-1-ol-derivatives
NZ200429A (en) * 1981-04-30 1984-10-19 Smith & Nephew Ass Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye
US4730013A (en) * 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4517199A (en) * 1981-11-20 1985-05-14 Alcon Laboratories, Inc. Method for lowering intraocular pressure using phenylimino-imidazoles
US4461904A (en) * 1981-11-20 1984-07-24 Alcon Laboratories, Inc. 2-(Trisubstituted phenylimino)-imidazolines
US4515800A (en) * 1981-11-20 1985-05-07 Icilio Cavero Method of lowering intraocular pressure using phenylimino-imidazoles
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4614825A (en) * 1982-05-17 1986-09-30 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane and 7-oxabicycloheptene compounds
US4576962A (en) * 1983-10-19 1986-03-18 The Procter & Gamble Company Prostaglandin analogues
DE3347128A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 9-halogen-(delta)(pfeil hoch)2(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4587257A (en) * 1984-12-14 1986-05-06 Alcon Laboratories, Inc. Control of ocular bleeding using clonidine derivatives
DE3871596T3 (de) * 1987-04-03 2000-09-07 Pharmacia & Upjohn Ab, Stockholm Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
IL87116A (en) * 1987-07-17 1993-03-15 Schering Ag 9-halogen-(z)-prostaglandin derivatives and pharmaceutical compositions containing the same
WO1990002553A1 (en) * 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP0366279B1 (en) * 1988-10-01 1994-09-21 R-Tech Ueno Ltd. Ocular hypotensive agents
CA2014038A1 (en) * 1989-05-25 1990-11-25 Charles Gluchowski Intraocular pressure reducing 15-acyl prostaglandins
DE3923797A1 (de) * 1989-07-14 1991-01-24 Schering Ag 9-fluor-prostaglandin-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5093329A (en) * 1990-03-12 1992-03-03 Allergan, Inc. Intraocular pressure reducing prostaglandin-like 7-oxabicyclo derivatives
WO1991014428A1 (en) * 1990-03-19 1991-10-03 Allergan, Inc. USE OF 5-TRANS PROSTAGLANDIN F2α AS AN OCULAR HYPOTENSIVE AGENT
ATE117208T1 (de) * 1990-05-22 1995-02-15 R Tech Ueno Ltd Behandlung von intraokularem druck mit einer ophthalmischen synergistischen kombination.
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions

Also Published As

Publication number Publication date
EP0664707B1 (en) 1997-06-04
CA2146127C (en) 2000-06-13
HK1007102A1 (en) 1999-04-01
EP0664707A1 (en) 1995-08-02
DE69311361T2 (de) 1998-01-08
US5480900A (en) 1996-01-02
JPH08502485A (ja) 1996-03-19
US5605922A (en) 1997-02-25
AU674038B2 (en) 1996-12-05
US5811443A (en) 1998-09-22
AU5328694A (en) 1994-05-09
WO1994008585A1 (en) 1994-04-28
JP3002258B2 (ja) 2000-01-24
ATE153855T1 (de) 1997-06-15
DE69311361D1 (de) 1997-07-10

Similar Documents

Publication Publication Date Title
ES2105333T3 (es) Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.
ES2186670T3 (es) Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular.
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
ES2458493T8 (es) Composición oftálmica tópica de fluprostenol para el tratamiento del glaucoma y de la hipertensión ocular
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
ES2061094T3 (es) Un procedimiento para la obtencion de una formulacion para disminuir el deseo imperioso de alcohol (craving) en el tratamiento del alcoholismo cronico.
KR930001913A (ko) 안염 치료방법
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
ES2144980T1 (es) Metodos y composiciones para tratar la rinitis alergica y otros trastornos, empleando descarboetoxiloratadina.
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
MX9204703A (es) Acidos n-acil-n-heterociclilalquilamino, proceso para su obtencion y composicion farmaceutica que los contiene.
ES2178291T3 (es) Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a.
ECSP941122A (es) Derivados de 5-arilindoles
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
SE8703854D0 (sv) Prostaglandinderivat for behandling av glaukom eller okuler hypertension
ATE78465T1 (de) Kathartica.
ES2038074A1 (es) Nuevos derivados de benzimidazol, su preparacion y su aplicacion como medicamentos.
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
ATE242220T1 (de) Benzimidazolderivate mit dopaminerger wirkung
ES2065980T3 (es) Uso del acido 5-aminosalicilico en el tratamiento de alteraciones dermatologicas.
DE69206262D1 (de) Oxalon Und Hypotensive 2-Decarboxyl-2 Azylthioalkyl Prostagladin-Derivate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 664707

Country of ref document: ES